Cameroon is Lagging Behind in the Provision of Art Services: Message from Artificial Neural Networks
Abstract
In this piece of
work, the ANN approach was applied to analyze ART coverage in Cameroon. The
employed annual data covers the period 2000-2019 and the out-of-sample period
ranges over the period 2019-2023. The residuals and forecast evaluation
criteria (Error, MSE and MAE) of the applied model indicate that the model is
stable in forecasting ART coverage in Cameroon. The ANN (9,12,1) model
predictions suggest that the country is likely to have a low ART coverage of 53
% over the period 2019-2023.Therefore the government is strongly encouraged to
intensify demand creation for HIV testing and ART services ,address barriers
for accessing ART and source more funding for ART medicines to meet the
increased demand amongst other measures.
Country : Zimbabwe
1 Dr. Smartson. P. NYONI2 Thabani NYONI
ZICHIRe Project, University of Zimbabwe, Harare, Zimbabwe
Department of Economics, University of Zimbabwe, Harare, Zimbabwe
Kouanfack C, Laurent C, Peytavin G,
Ciaffi L, Ngolle M, Nkene YM, et al. Adherence to antiretroviral therapy
assessed by drug level monitoring and self-report in cameroon. J Acquir Immune
Defic Syndr. 2008; 48(2):216–9. doi: 10.1097/QAI.0b013e3181743955 PMID:
18520681
Mbuagbaw L, Thabane L, Ongolo-Zogo
P, Lester RT, Mills EJ, Smieja M, et al. The Cameroon Mobile Phone SMS (CAMPS)
trial: a randomized trial of text messaging versus usual care for adherence to
antiretroviral therapy. PLoS One. 2012; 7(12):e46909. PubMed Central PMCID:
PMCPMC3516507. doi: 10.1371/journal.pone.0046909 PMID: 23236345
Meresse M, Carrieri MP, Laurent C,
Kouanfack C, Protopopescu C, Blanche J, et al. Time patterns of adherence and
long-term virological response to non-nucleoside reverse transcriptase
inhibitor regimens in the Stratall ANRS 12110/ESTHER trial in Cameroon. Antivir
Ther. 2013; 18(1):29–37. doi: 10. 3851/IMP2535 PMID: 23358393
Pefura-Yone EW, Soh E, Kengne AP,
Balkissou AD, Kuaban C. Non-adherence to antiretroviral therapy in Yaounde:
prevalence, determinants and the concordance of two screening criteria. J
Infect Public Health. 2013; 6(4):307–15. doi: 10.1016/j.jiph.2013.02.003 PMID:
23806707
PLOS ONE |
DOI:10.1371/journal.pone.0170893 January 31, 2017 16 / 19
Rougemont M, Stoll BE, Elia N,
Ngang P. Antiretroviral treatment adherence and its determinants in Sub-Saharan
Africa: a prospective study at Yaounde Central Hospital, Cameroon. AIDS Res Ther.
2009; 6:21. PubMed Central PMCID: PMCPMC2770068. doi: 10.1186/1742-6405-6-21
PMID: 19821997 10.
Roux P, Kouanfack C, Cohen J,
Marcellin F, Boyer S, Delaporte E, et al. Adherence to antiretroviral treatment
in HIV-positive patients in the Cameroon context: promoting the use of
medication reminder methods. J Acquir Immune Defic Syndr. 2011; 57 Suppl
1:S40–3.
UNAIDS. Cameroon. 2014 Progress
report on the global plan. Towards the elimination of new HIV infections among
children by 2015 and keeping their mothers alive. UNAIDS Country Report. 2014
UNAIDS. Cameroon—Antiretroviral
therapy coverage (% of people living with HIV). Index mundi: http://
wwwindexmundicom/facts/cameroon/antiretroviral-therapy-coverage2015. 6. Bank W.
Antiretroviral therapy coverage (% of people with advanced HIV infection) in
Cameroon. World Bank Indicators -Cameroon.
2016;http://www.tradingeconomics.com/cameroon/antiretroviraltherapy-coverage-percent-of-people-with-advanced-hiv-infection-wb-data.html
WHO. Global Health Observatory (GHO)
data. Antiretroviral therapy (ART (coverage among all age groups. World Health
Organization. 2015;http://www.who.int/gho/hiv/epidemic_response/ART_text/
